Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4767186 | 0.84 | MAPT (0.46) | KMT2ASLC2A1HRH3RXFP1MAPT | |
| Trifluoroacetic Acid SCHEMBL4775692 | 0.82 | RAB9A (0.52) | KMT2ASLC2A1HRH3RXFP1MAPT | |
| Trifluoroacetic Acid SCHEMBL4774281 | 0.80 | SLC2A1 (0.58) | KMT2ASLC2A1HRH3RXFP1MAPT | |
| Trifluoroacetic Acid SCHEMBL4772603 | 0.80 | SLC2A1 (0.50) | KMT2ASLC2A1HRH3MAPTL3MBTL3 | |
| Trifluoroacetic Acid SCHEMBL4770823 | 0.79 | SLC2A1 (0.47) | SLC2A1HRH3MAPTL3MBTL3L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL4767916 | 0.78 | TMPRSS2 (0.55) | KMT2ASLC2A1HRH3MAPTTRPV1 | |
| SCHEMBL4775136 | 0.78 | HRH3 (0.43) | KMT2ASLC2A1HRH3RXFP1MAPT | |
| SCHEMBL4765391 | 0.78 | RXFP1 (0.51) | KMT2AHRH3RXFP1MAPTL3MBTL3 | |
| Trifluoroacetic Acid SCHEMBL4775302 | 0.78 | MAPT (0.48) | KMT2ASLC2A1MAPT | |
| Trifluoroacetic Acid SCHEMBL4767622 | 0.77 | HRH3 (0.51) | SLC2A1HRH3TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | KMT2A 99/4885SLC2A1 4665/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.